Fibrosis can affect virtually all organs and tissues. In the case of physical or vascular trauma, repairative fibrosis such as wound healing is critical for survival. However, when the fibrotic response becomes dysregulated either as an extended response to injury (e.g. cardiac fibrosis) or as a secondary response to proinflammaory cytokines/growth factors (e.g. cancer stroma) it will result in diseases with devastating pathologies. NovoMedix has developed a series of novel orally available small molecules with wide therapeutic windows to treat fibrotic diseases. The initial targeted indication will be Liver Fibrosis with the goal of rapid delivery of this first-in-class therapy to patients. Additional indications include Heart, Lung, and Kidney fibrosis as well cancers that are highly dependent on the stroma such as pancreatic and breast.